Quick To Clinic Viral Vector Services

Advancing gene therapies through the development lifecycle from preclinical studies to clinical and commercial manufacturing is a complex process. Sponsors must navigate an evolving regulatory landscape that is responding to the latest scientific advancements as well as a lack of expertise across this relatively nascent industry.

Thermo Fisher’s end-to-end manufacturing service enables the production of high-performance, scalable, AAV and lentiviral vectors. Learn how a partner with the right knowledge and experience can de-risk timelines, ensure regulatory compliance, and reduce the potential for additional or surprising out-of-pocket costs.